2026 Artemetrx State of Specialty Spend and Trend Report
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
Insights
Categories
Topics
Categories
Topics
Why Pharmacy Benefit Auditing is Critical for Effective Oversight
Leveraging Audits To Build Strategic Advantage Key Points Auditing is essential for navigating pharmacy benefit complexity and ensuring strategic oversight. Key events like vendor…
Read Post
Annual Spending on Specialty Drugs Continues to Increase but at a Slower Pace Than Prior Years, Driven in Part by Biosimilar Adoption.
DALLAS, TX – August 5, 2025 – Pharmaceutical Strategies Group (“PSG”), an EPIC company, released the Artemetrx State of Specialty Spend…
Read Post
2025 Artemetrx State of Specialty Spend and Trend Report
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
5 Aspects of a Quality Pharmacy Benefits Procurement/RFP
Ensure Your Consultant and Procurement are Best-in-Class Ten to fifteen years ago, pharmacy benefit manager (PBM) procurements were relatively simple: plan sponsors would go…
Read Post
Integrated Insights, Clinical Connections: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Leverage Integrated Data to Inform Better Benefit Decisions An estimated 22 million U.S. adults are affected by a chronic liver condition called metabolic dysfunction-associated…
Read Post
2025 Artemetrx State of Specialty Spend and Trend Report Webinar
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
PSG Enhances Artemetrx GeneCQ™ with Expanded Pipeline Intelligence to Help Healthcare Payers Navigate Growing Gene Therapy Market
Enhanced Platform Helps Payers Proactively Manage Gene Therapy Costs While Ensuring Patient Access DALLAS, TX – June 12, 2025 – Pharmaceutical Strategies Group (“…
Read Post
Multi-Million Dollar Gene Therapy ZEVASKYN™ Increases Health Care Cost in Rare Skin Disorder – Recessive Dystrophic Epidermolysis Bullosa
Will This Gene Therapy Break Payers’ Budgets? Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a severe, inherited skin disorder that has no cure, and until…
Read Post
2025 Trends in Drug Benefit Design Report
PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…
Read Post
PSG Releases 2025 Drug Benefit Design Report: PBM Unbundling Gains Momentum and Payers Navigate GLP-1 Coverage Decisions Amid Rising Costs
New Research Reveals Strategic Approaches to Balancing Member Access and Affordability with Pharmacy Spend Control DALLAS, TX – June 10, 2025 – Pharmaceutical Strategies…
Read Post
GLP-1 Spotlight: Navigating Coverage, Costs, and Clinical Outcomes
Join us for an in-depth exploration of one of the most impactful developments in prescription drug benefits: GLP-1 medications for type 2 diabetes and…
Read Post